The pharmaceutical and diagnostic sectors are undergoing a profound structural shift away from reactive, standardized treatments toward predictive, patient-specific therapeutic strategies. As oncology, neurology, and immunology drug pipelines demand greater clinical trial efficiency and higher success rates, biopharmaceutical researchers rely heavily on biological indicators to stratify patient...
French
